BEIJING, June 17, 2014 /PRNewswire/ -- China Biologic
Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a
leading plasma-based biopharmaceutical company in China, today announced that it filed a
preliminary prospectus supplement in connection with the
commencement of a public offering of shares of its common stock.
The Company plans on selling 1,000,000 shares of common stock and
certain selling stockholders plan on selling 2,212,500 shares of
common stock in the offering. In addition, the Company has granted
the underwriters a 30-day option to purchase up to 481,875
additional shares of common stock. The final terms of the offering
will depend on market and other conditions at the time of
pricing.
The Company intends to use the proceeds that it receives from
the offering primarily for general corporate purposes. In addition,
if appropriate opportunities arise in the future to acquire or
invest in complementary products, technologies or businesses, the
Company may use a portion of the net proceeds for such acquisition
or investment. The Company will not receive any proceeds from the
sale of shares by the selling stockholders.
Morgan Stanley & Co. International plc will act as the sole
book-running manager for the offering and Aegis Capital Corp. will
act as a co-manager.
The offering will be made pursuant to three shelf registration
statements that are already effective with the Securities and
Exchange Commission (the "SEC"). A preliminary prospectus
supplement and the accompanying prospectuses relating to the
offering have been filed with the SEC and are available on its
website at www.sec.gov. Copies of the preliminary prospectus
supplement and the accompanying prospectuses, when available, may
also be obtained by contacting (i) Morgan Stanley, Prospectus
Department, 180 Varick Street, 2nd Floor, New York, NY, 10014, United States of America, or by calling
1-866-718-1649, or by email at prospectus@morganstanley.com; or
(ii) Aegis Capital Corp., Prospectus Department, 810 Seventh
Avenue, 18th Floor, New York, NY,
10019, or by calling 212-813-1010, or by email at
prospectus@aegiscap.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor may there be any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. The offering of these securities will be made only by
means of the prospectus supplement and accompanying
prospectuses.
About China Biologic
China Biologic is a leading plasma-based biopharmaceutical
company in China. The Company's
products are used as critical therapies during medical emergencies
and for the prevention and treatment of life-threatening diseases
and immune-deficiency related diseases. China Biologic is
headquartered in Beijing and
manufactures over 20 different dosages of plasma-based products
through its indirect majority-owned subsidiaries, Shandong Taibang
Biological Products Co., Ltd. and Guizhou Taibang Biological
Products Co., Ltd. The Company also has an equity investment in
Xi'an Huitian Blood Products Co., Ltd. The Company sells its
products to hospitals and inoculation centers, as well as
distributors, in China. For
additional information, please see the Company's website
www.chinabiologic.com.
Cautionary Note Regarding Forward-Looking Statements
This release contains forward-looking statements about the
proposed offering and the use of the offering proceeds that involve
risks and uncertainties. Any forward-looking statements and all
other statements that may be made in this news release that are not
historical facts are subject to a number of risks and
uncertainties, and actual results may differ materially. Specific
risks include stock market conditions and our ability to complete
the offering on acceptable terms. Please refer to China Biologic
filings with the SEC for more information on the risk factors that
could cause our actual results to differ. The Company assumes no
obligation and does not intend to update these forward-looking
statements, except as required by law.
Contact:
China Biologic Products, Inc.
Mr. Ming Yin
Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com
ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: william.zima@icrinc.com
SOURCE China Biologic Products, Inc.